株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

難治性慢性咳嗽(CRC)- 市場洞察、疫学、予測

Chronic Refractory Cough (CRC)- Market Insights, Epidemiology, and Market Forecast - 2028

発行 DelveInsight Business Research LLP 商品コード 905942
出版日 ページ情報 英文 147 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=110.43円で換算しております。
Back to Top
難治性慢性咳嗽(CRC)- 市場洞察、疫学、予測 Chronic Refractory Cough (CRC)- Market Insights, Epidemiology, and Market Forecast - 2028
出版日: 2019年08月01日 ページ情報: 英文 147 Pages
概要

当レポートでは、主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)の難治性慢性咳嗽(CRC)市場を調査し、疾病の概要や現行の治療法、新薬のプロファイル、全体および各国の市場動向、疫学的予測、市場規模、有病数の推移と予測、アンメットニーズ、市場の成長要因および障壁などを包括的にまとめています。

目次

第1章 重要洞察

第2章 市場概要

  • 市場シェア(実績値)
  • 市場シェア(予測値)

第3章 疾病背景と概要

  • イントロダクション
  • 兆候と症状
  • 原因
  • 危険因子
  • 慢性咳嗽のメカニズム
  • 慢性咳嗽の病態生理
  • 難治性慢性咳嗽と他の神経障害の類似性
  • 難治性慢性咳嗽の病因
  • 難治性慢性咳嗽の臨床的特徴
  • 診断

第4章 疫学と患者人口

  • 主要7カ国の難治性慢性咳嗽(CRC)患者数
  • 主要7カ国の難治性慢性咳嗽(CRC)診断数

第5章 難治性慢性咳嗽の疫学:国別

  • 米国
    • 仮定と根拠
    • 慢性咳嗽の有病数
    • 慢性咳嗽の有病数:性別
    • 難治性慢性咳嗽の有病数
    • 難治性慢性咳嗽の診断数
    • 特発性肺線維症(IPF)患者における難治性慢性咳嗽の有病数
  • EU5カ国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国
  • 日本

第6章 難治性慢性咳嗽(CRC)の治療

  • 末梢性
    • TRPチャネル
    • プリン受容体
    • 電位依存性ナトリウムチャンネル
  • 中枢性
    • オピエート(硫酸モルヒネ/コデイン/トラマドール)
    • GABA関連化合物(ガバペンチン、プレガバリン)
    • N-メチル-D-アスパラギン酸(NMDA)受容体
    • アミトリプチリン
    • タキキニン受容体拮抗薬
    • ニコチン性アセチルコリン受容体
  • 慢性咳嗽管理

第7章 米国の難治性慢性咳嗽(CRC)ガイドライン

第8章 アンメットニーズ

第9章 新薬

  • キークロスコンペティション
  • Gefapixant:Merck
    • 製品概要
    • 開発動向
    • 臨床開発
    • 製品プロファイル
  • Orvepitant Maleate:Nerre Therapeutics
  • BLU-5937:Bellus Health
  • Bradanicline:Attenua
  • RVT-1601:Respivant Sciences
  • S-600918:塩野義製薬

第10章 主要7カ国の難治性慢性咳嗽(CRC)市場

  • 主な調査結果
  • 主要7カ国の市場規模

第11章 米国市場の見通し

  • 米国の市場規模
    • 総市場規模
    • 市場規模:治療薬別

第12章 欧州5カ国市場の見通し

  • ドイツ
    • 総市場規模
    • 市場規模:治療薬別
  • フランス
  • イタリア
  • スペイン
  • 英国
  • 日本

第13章 市場成長要因

第14章 市場の障壁

第15章 付録

  • 調査方法

第16章 DelveInsightのサービス内容

第17章 免責事項

第18章 DelveInsightについて

図表

List of Tables

  • Table 1 Total Population of Chronic Refractory Cough in the 7MM (2017-2028)
  • Table 2 Total Diagnosed Population of Chronic Refractory Cough in the 7MM (2017-2028)
  • Table 3 Chronic Cough Prevalent Population in the United States (2017-2028)
  • Table 4 Chronic Cough Gender-wise Prevalent Population in the United States (2017-2028)
  • Table 5 Chronic Refractory Cough Prevalent Population in the United States (2017-2028)
  • Table 6 Chronic Refractory Cough Diagnosed Prevalent Population in the United States (2017-2028)
  • Table 7 Chronic Refractory Cough Diagnosed Prevalent Population in IPF patients in the United States (2017-2028)
  • Table 8: Chronic Cough Prevalent Population in Germany (2017-2028)
  • Table 9 Chronic Cough Gender-wise Prevalent Population in Germany (2017-2028)
  • Table 10 Chronic Refractory Cough Prevalent Population in Germany (2017-2028)
  • Table 11 Chronic Refractory Cough Diagnosed Prevalent Population in Germany (2017-2028)
  • Table 12 Chronic Refractory Cough Diagnosed Prevalent Population in IPF patients in Germany (2017-2028)
  • Table 13 Chronic Cough Prevalent Population in France (2017-2028)
  • Table 14 Chronic Cough Gender-wise Prevalent Population in France (2017-2028)
  • Table 15 Chronic Refractory Cough Prevalent Population in France (2017-2028)
  • Table 16 Chronic Refractory Cough Diagnosed Prevalent Population in France (2017-2028)
  • Table 17 Chronic Refractory Cough Diagnosed Prevalent Population in IPF patients in France (2017-2028)
  • Table 18 Chronic Cough Prevalent Population in Italy (2017-2028)
  • Table 19 Chronic Cough Gender-wise Prevalent Population in Italy (2017-2028)
  • Table 20 Chronic Refractory Cough Prevalent Population in Italy (2017-2028)
  • Table 21 Chronic Refractory Cough Diagnosed Prevalent Population in Italy (2017-2028)
  • Table 22 Chronic Refractory Cough Diagnosed Prevalent Population in IPF patients in Italy (2017-2028)
  • Table 23 Chronic Cough Prevalent Population in Spain (2017-2028)
  • Table 24 Chronic Cough Gender-wise Prevalent Population in Spain (2017-2028)
  • Table 25 Chronic Refractory Cough Prevalent Population in Spain (2017-2028)
  • Table 26 Chronic Refractory Cough Diagnosed Prevalent Population in Spain (2017-2028)
  • Table 27 Chronic Refractory Cough Diagnosed Prevalent Population in IPF patients in Spain (2017-2028)
  • Table 28 Chronic Cough Prevalent Population in the United Kingdom (2017-2028)
  • Table 29 Chronic Cough Gender-wise Prevalent Population in the United Kingdom (2017-2028)
  • Table 30 Chronic Refractory Cough Prevalent Population in the United Kingdom(2017-2028)
  • Table 31 Chronic Refractory Cough Diagnosed Prevalent Population in the United Kingdom (2017-2028)
  • Table 32 Chronic Refractory Cough Diagnosed Prevalent Population in IPF patients in the United Kingdom (2017-2028)
  • Table 33 Prevalent Population of Chronic Cough in Japan (2017-2028)
  • Table 34 Gender-wise Prevalent Population of Chronic Cough in Japan (2017-2028)
  • Table 35 Prevalent Population of Chronic Refractory Cough in Japan(2017-2028)
  • Table 36 Diagnosed Prevalent Population of Chronic Refractory Cough in Japan (2017-2028)
  • Table 37 Diagnosed Prevalent Population of Chronic Refractory Cough in IPF patients in Japan (2017-2028)
  • Table 38 Comparison of cough guidelines in relation to chronic refractory cough (CRC)
  • Table 39 Comparison of Emerging Drugs Under Development
  • Table 40 Gefapixant, Clinical Trial Description
  • Table 41 Orvepitant Maleate, Clinical Trial Description
  • Table 42 BLU-5937, Clinical Trial Description
  • Table 43 Bradanicline, Clinical Trial Description
  • Table 44 RVT-1601, Clinical Trial Description
  • Table 45 S-600918, Clinical Trial Description
  • Table 46 7 Major Market Size of Chronic Refractory Cough in USD Million (2017-2028)
  • Table 47 United States Market Size of Chronic Refractory Cough, USD Million (2017-2028)
  • Table 48 Market size of Chronic Refractory Cough by therapies in the United States, in USD Million (2017-2028)
  • Table 49 Market Size of Chronic Refractory Cough in Germany, in USD Million (2017-2028)
  • Table 50 Market size of Chronic Refractory Cough by therapies in Germany, in USD Million (2017-2028)
  • Table 51 Market Size of Chronic Refractory Cough in France, in USD Million (2017-2028)
  • Table 52 Market size of Chronic Refractory Cough by therapies in France, in USD Million (2017-2028)
  • Table 53 Market Size of Chronic Refractory Cough in Italy, in USD Million (2017-2028)
  • Table 54 Market size of Chronic Refractory Cough by therapies in Italy, in USD Million (2017-2028)
  • Table 55 Market Size of Chronic Refractory Cough in Spain, in USD Million (2017-2028)
  • Table 56 Market size of Chronic Refractory Cough by therapies in Spain, in USD Million (2017-2028)
  • Table 57 Market Size of Chronic Refractory Cough in the UK, in USD Million (2017-2028)
  • Table 58 Market size of Chronic Refractory Cough by therapies in the United Kingdom, in USD Million (2017-2028)
  • Table 59 Market Size of Chronic Refractory Cough in Japan, in USD Million (2017-2028)
  • Table 60 Market size of Chronic Refractory Cough by therapies in Japan, in USD Million (2017-2028)

List of Figures

  • Figure 1 Symptoms of Chronic Refractory Cough
  • Figure 2 Origins and neurological pathways of the cough reflex.
  • Figure 3 Total Patient Population of Chronic Refractory Cough in the 7MM (2017-2028)
  • Figure 4 Total Diagnosed Patient Population of Chronic Refractory Cough in the 7MM (2017-2028)
  • Figure 5 Chronic Cough Prevalent Population in the United States (2017-2028)
  • Figure 6 Chronic Cough Gender-wise Prevalent Population in the United States (2017-2028)
  • Figure 7 Chronic Refractory Cough Prevalent Population in the United States (2017-2028)
  • Figure 8 Chronic Refractory Cough Diagnosed Prevalent Population in the United States (2017-2028)
  • Figure 9 Chronic Refractory Cough Diagnosed Prevalent Population in IPF patients in the United States (2017-2028)
  • Figure 10 Chronic Cough Prevalent Population in Germany (2017-2028)
  • Figure 11 Chronic Cough Gender-wise Prevalent Population in Germany (2017-2028)
  • Figure 12 Chronic Refractory Cough Prevalent Population in Germany (2017-2028)
  • Figure 13 Chronic Refractory Cough Diagnosed Prevalent Population in Germany (2017-2028)
  • Figure 14 Chronic Refractory Cough Diagnosed Prevalent Population in IPF patients in Germany (2017-2028)
  • Figure 15 Chronic Cough Prevalent Population in France (2017-2028)
  • Figure 16 Chronic Cough Gender-wise Prevalent Population in France (2017-2028)
  • Figure 17 Chronic Refractory Cough Prevalent Population in France (2017-2028)
  • Figure 18 Chronic Refractory Cough Diagnosed Prevalent Population in France (2017-2028)
  • Figure 19 Chronic Refractory Cough Diagnosed Prevalent Population in IPF patients in France (2017-2028)
  • Figure 20 Chronic Cough Prevalent Population in Italy (2017-2028)
  • Figure 21 Chronic Cough Gender-wise Prevalent Population in Italy (2017-2028)
  • Figure 22 Chronic Refractory Cough Prevalent Population in Italy (2017-2028)
  • Figure 23 Chronic Refractory Cough Diagnosed Prevalent Population in Italy (2017-2028)
  • Figure 24 Chronic Refractory Cough Diagnosed Prevalent Population in IPF patients in Italy (2017-2028)
  • Figure 25 Chronic Cough Prevalent Population in Spain (2017-2028)
  • Figure 26 Chronic Cough Gender-wise Prevalent Population in Spain (2017-2028)
  • Figure 27 Chronic Refractory Cough Prevalent Population in Spain (2017-2028)
  • Figure 28 Chronic Refractory Cough Diagnosed Prevalent Population in Spain (2017-2028)
  • Figure 29 Chronic Refractory Cough Diagnosed Prevalent Population in IPF patients in Spain (2017-2028)
  • Figure 30 Chronic Cough Prevalent Population in the United Kingdom (2017-2028)
  • Figure 31 Chronic Cough Gender-wise Prevalent Population in the United Kingdom (2017-2028)
  • Figure 32 Chronic Refractory Cough Prevalent Population in the United Kingdom(2017-2028)
  • Figure 33 Chronic Refractory Cough Diagnosed Prevalent Population in the United Kingdom (2017-2028)
  • Figure 34 Chronic Refractory Cough Diagnosed Prevalent Population in IPF patients in the United Kingdom (2017-2028)
  • Figure 35 Prevalent Population of Chronic Cough in Japan (2017-2028)
  • Figure 36 Gender-wise Prevalent Population of Chronic Cough in Japan (2017-2028)
  • Figure 37 Prevalent Population of Chronic Refractory Cough in Japan(2017-2028)
  • Figure 38 Diagnosed Prevalent Population of Chronic Refractory Cough in Japan (2017-2028)
  • Figure 39 Diagnosed Prevalent Population of Chronic Refractory Cough in IPF patients in Japan (2017-2028)
  • Figure 40 A proposed algorithm detailing a management approach to the patient with "difficult-to-treat" cough
  • Figure 41 Unmet Needs for Chronic Refractory Cough
  • Figure 42 7 Major Market Size of Chronic Refractory Cough in USD Million (2017-2028)
  • Figure 43 Market Size of Chronic Refractory Cough in the United States, USD Millions (2017-2028)
  • Figure 44 Market size of Chronic Refractory Cough by therapies in the US, in USD Million (2017-2028)
  • Figure 45 Market Size of Chronic Refractory Cough in Germany, USD Million (2017-2028)
  • Figure 46 Market Size of Chronic Refractory Cough by therapies, in Germany, in USD Million (2017-2028)
  • Figure 47 Market Size of Chronic Refractory Cough in France, USD Million (2017-2028)
  • Figure 48 Market Size of Chronic Refractory Cough by therapies, in France, in USD Million (2017-2028)
  • Figure 49 Market Size of Chronic Refractory Cough in Italy, USD Million (2017-2028)
  • Figure 50 Market Size of Chronic Refractory Cough by therapies, in Italy, in USD Million (2017-2028)
  • Figure 51 Market Size of Chronic Refractory Cough in Spain, USD Million (2017-2028)
  • Figure 52 Market Size of Chronic Refractory Cough by therapies in Spain, in USD Million (2017-2028)
  • Figure 53 Market Size of Chronic Refractory Cough in the UK, USD Million (2017-2028)
  • Figure 54 Market Size of Chronic Refractory Cough by therapies in the UK, in USD Million (2017-2028)
  • Figure 55 Market Size of Chronic Refractory Cough in Japan, USD Million (2017-2028)
  • Figure 56 Market Size of Chronic Refractory Cough by therapies in Japan, in USD Million (2017-2028)
  • Figure 57 Market Drivers
  • Figure 58 Market Barriers
目次
Product Code: DIMI0626

DelveInsight's 'Chronic Refractory Cough (CRC)- Market Insights, Epidemiology, and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Chronic Refractory Cough (CRC) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Chronic Refractory Cough (CRC) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

Chronic Refractory Cough (CRC) - Disease Understanding and Treatment Algorithm

Chronic refractory cough (CRC) is defined as a cough lasting more than 8 weeks that persists despite guidelines based treatment which may be treated by different medical specialties: Pulmonology, Allergy, and Immunology, Digestive Health and Otorhinolaryngology. Patients with chronic cough experience impaired quality of life and interruption of activities of daily living. It can result in depression and can persist for many months or years, despite systematic investigation and treatment of known causes. The infection can also be referred to as chronic cough, chronic idiopathic cough, unexplained chronic cough, and cough hypersensitivity syndrome. CRC is typically nonproductive and there is often a preceding history of viral respiratory tract infection. Patients frequently describe a dry, irritating cough which may be localized to the laryngeal region. Chronic cough lasts more than 8 weeks and can be caused by gastroesophageal reflux disease (GERD), postnasal drip from sinus infections or allergies, or chronic lung conditions, such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and interstitial lung diseases.

The DelveInsight Chronic Refractory Cough market report gives the thorough understanding of the Chronic Refractory Cough by including details such as disease introduction, signs and symptoms, causes, risk factors, mechanism of Chronic cough, pathophysiology, the similarity between Chronic Refractory Cough and other neuropathic disorder diagnoses, pathogenesis, clinical features of CRC and diagnosis. It also provides treatment algorithms and treatment guidelines for Chronic Refractory Cough in the US, Europe, and Japan.

Chronic Refractory Cough (CRC) Epidemiology

In the United States, cough is the most common complaint for which patients seek medical attention and is the second most common reason for a general medical examination, accounting for more than 26 million office visits annually. Cough often results from an acute, self-limited, viral upper respiratory tract infection; however, there are multiple causes of cough beyond this, including both respiratory tract and nonrespiratory tract-related etiologies. Cough that lasts more than 8 weeks is considered to be chronic as per defined by the American College of Chest Physicians (ACCP). The cough becomes chronic if it persists, often due to an underlying etiology that is difficult to diagnose or treat.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of Chronic Refractory Cough in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2028 for the following aspects:

  • Prevalent Population of Chronic Cough
  • Gender-wise Prevalent Population of Chronic Cough
  • Prevalent Population of Chronic Refractory Cough
  • Diagnosed Prevalent Population of Chronic Refractory Cough
  • Diagnosed Prevalent Population of Chronic Refractory Cough in Idiopathic Pulmonary Fibrosis (IPF) patients

According to a study conducted by Jun et al. titled "Effect of pregabalin for the treatment of chronic refractory cough," which stated that nearly 11-16% of patients suffer from chronic refractory cough during their life. Although many patients had received satisfactory treatment, there were still 20-40% of patients who suffered long-term cough symptoms even after standardized treatment. The study was concluded stating that an innovative treatment with fewer adverse effects and long-term relief was necessary for CRC patients.

According to a study conducted by Weinberger et al. titled "Long-lasting cough in an adult German population: incidence, symptoms, and related pathogens" researchers assessed the burden of suffering related to prolonged coughing and tried to identify further causative agents. It was found that incidence of pertussis in adults have shown that it accounted for only approximately 5-15% cases of prolonged coughing in which, symptoms were not indicative of a specific agent and a total of 64% of patients received antibiotics. The study was concluded by stating that prolonged adult coughing required medical attention, which prompted substantial healthcare use.

Chronic Refractory Cough (CRC) Drug Chapters

This segment of the Chronic Refractory Cough report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

To meet the increasing demand for the treatment of Chronic Refractory Cough, companies have shifted their focus toward the development of targeted therapies. Expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the prevalent population of Chronic Refractory Cough and awareness of the disease. The overall dynamics of Chronic Refractory Cough market is anticipated to change in the coming years owing to the expected launch of emerging therapies of the major key players, such as Merck, Nerre Therapeutics, Bellus Health, Attenua, Respivant Sciences, and Shionogi and Bayer will significantly increase the market during the forecast period (2019-2028).

Chronic Refractory Cough (CRC) Market Outlook

Chronic refractory cough proves to be a huge burden on the patients who are fighting this debilitating condition. CRC is typically nonproductive and there is often a preceding history of viral respiratory tract infection. Patients frequently describe a dry, irritating cough, which may be localized to the laryngeal region. It significantly impairs patients' quality of life. Unfortunately, in many situations, patients continue to experience CRC in spite of following published guidelines for diagnosis and treatment.

Currently, the market holds no approved therapy to treat chronic refractory cough. According to the recent guidelines published by the American College of Chest Physicians (ACCP) four categories of treatment can be implemented which include nonpharmacologic therapies, inhaled corticosteroids, neuromodulatory therapies, and other therapies.

The market of CRC is mainly dominated by nonpharmacologic therapies, which include Speech Therapy and Physiotherapy. The market also holds various types of pharmacologic therapies, which include Neuromodulators, Proton pump inhibitors, Inhaled Corticosteroids, and other treatment options. Opiates (morphine, codeine, tramadol, etc.), gabapentin, pregabalin, morphine, amitriptyline, and baclofen, which act on the heightened neural sensitization, and is involved in the pathogenesis of CRC. There are several other treatment options also followed for the CRC patients. Since, CRC is an outcome of several disorders, such as Gastroesophageal reflux disease (GORD), asthma, bronchitis, etc. A drug like esomeprazole, which is a proton pump inhibitor helps in relieving the acid-reflux in cough associated with GOR. Another drug Ipratropium bromide is used as a bronchodilator, which can provide short-term relief from cough.

This segment gives a thorough detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market, and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Chronic Refractory Cough in 7MM is expected to change from 2019 to 2028.

Chronic Refractory Cough (CRC) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017 to 2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Expected launch of therapies for Chronic Refractory Cough (CRC), such as Gefapixant (Merck), RVT-1601 (Respivant Sciences), Orvepitant Maleate (Nerre Therapeutics), BLU-5937 (Bellus Health), Bradanicline (Attenua), S-600918 (Shionogi), BAY1902607 and BAY1817080 (Bayer), and other targeted therapies in the forecast period [2019-2028] will also create a positive impact on the Chronic Refractory Cough (CRC) market.

Chronic Refractory Cough (CRC) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Chronic Refractory Cough (CRC) Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Chronic Refractory Cough (CRC) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Chronic Refractory Cough (CRC) market.
  • Organize sales and marketing efforts by identifying the best opportunities for Chronic Refractory Cough (CRC) market.
  • To understand the future market competition in the Chronic Refractory Cough (CRC) market.

Table of Contents

1. Key Insights

2. Chronic Refractory Cough Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of Chronic Refractory Cough in 2017
  • 2.2. Market Share (%) Distribution of Chronic Refractory Cough in 2028

3. Disease Background and Overview: Chronic Refractory Cough (CRC)

  • 3.1. Introduction
  • 3.2. Signs and symptoms
  • 3.3. Causes
  • 3.4. Risk factors
  • 3.5. Mechanism of Chronic cough
  • 3.6. Pathophysiology of chronic cough
  • 3.7. Similarity between Chronic Refractory Cough and other neuropathic disorder
    • 3.7.1. Cough hypersensitivity syndrome and Chronic Refractory Cough
    • 3.7.2. Laryngeal hypersensitivity
  • 3.8. Pathogenesis of Chronic Refractory Cough
  • 3.9. Clinical features of CRC
  • 3.10. Diagnosis

4. Epidemiology and Patient Population: Key Findings

  • 4.1. 7MM Total Patient Population of Chronic Refractory Cough
  • 4.2. 7MM Total Diagnosed Patient Population of Chronic Refractory Cough

5. Country Wise-Epidemiology of Chronic Refractory Cough

  • 5.1. United States
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Chronic Cough Prevalent Population in the United States
    • 5.1.3. Chronic Cough Gender-wise Prevalent Population in the United States
    • 5.1.4. Chronic Refractory Cough Prevalent Population in the United States
    • 5.1.5. Chronic Refractory Cough Diagnosed Prevalent Population in the United States
    • 5.1.6. Chronic Refractory Cough Diagnosed Prevalent Population in Idiopathic Pulmonary Fibrosis (IPF) patients in the United States
  • 5.2. EU5 Countries
    • 5.2.1. Assumptions and Rationale
  • 5.3. Germany
    • 5.3.1. Chronic Cough Prevalent Population in Germany
    • 5.3.2. Chronic Cough Gender-wise Prevalent Population in Germany
    • 5.3.3. Chronic Refractory Cough Prevalent Population in Germany
    • 5.3.4. Chronic Refractory Cough Diagnosed Prevalent Population in Germany
    • 5.3.5. Chronic Refractory Cough Diagnosed Prevalent Population in Idiopathic Pulmonary Fibrosis (IPF) patients in Germany
  • 5.4. France
    • 5.4.1. Chronic Cough Prevalent Population in France
    • 5.4.2. Chronic Cough Gender-wise Prevalent Population in France
    • 5.4.3. Chronic Refractory Cough Prevalent Population in France
    • 5.4.4. Chronic Refractory Cough Diagnosed Prevalent Population in France
    • 5.4.5. Chronic Refractory Cough Diagnosed Prevalent Population in Idiopathic Pulmonary Fibrosis (IPF) patients in France
  • 5.5. Italy
    • 5.5.1. Chronic Cough Prevalent Population in Italy
    • 5.5.2. Chronic Cough Gender-wise Prevalent Population in Italy
    • 5.5.3. Chronic Refractory Cough Prevalent Population in Italy
    • 5.5.4. Chronic Refractory Cough Diagnosed Prevalent Population in Italy
    • 5.5.5. Chronic Refractory Cough Diagnosed Prevalent Population in Idiopathic Pulmonary Fibrosis (IPF) patients in Italy
  • 5.6. Spain
    • 5.6.1. Chronic Cough Prevalent Population in Spain
    • 5.6.2. Chronic Cough Gender-wise Prevalent Population in Spain
    • 5.6.3. Chronic Refractory Cough Prevalent Population in Spain
    • 5.6.4. Chronic Refractory Cough Diagnosed Prevalent Population in Spain
    • 5.6.5. Chronic Refractory Cough Diagnosed Prevalent Population in Idiopathic Pulmonary Fibrosis (IPF) patients in Spain
  • 5.7. United Kingdom
    • 5.7.1. Chronic Cough Prevalent Population in the United Kingdom
    • 5.7.2. Chronic Cough Gender-wise Prevalent Population in the United Kingdom
    • 5.7.3. Chronic Refractory Cough Prevalent Population in the United Kingdom
    • 5.7.4. Chronic Refractory Cough Diagnosed Prevalent Population in the United Kingdom
    • 5.7.5. Chronic Refractory Cough Diagnosed Prevalent Population in Idiopathic Pulmonary Fibrosis (IPF) patients in the United Kingdom
  • 5.8. Japan
    • 5.8.1. Assumptions and Rationale
    • 5.8.2. Chronic Cough Prevalent Population in Japan
    • 5.8.3. Chronic Cough Gender-wise Prevalent Population in Japan
    • 5.8.4. Chronic Refractory Cough Prevalent Population in Japan
    • 5.8.5. Chronic Refractory Cough Diagnosed Prevalent Population in Japan
    • 5.8.6. Chronic Refractory Cough Diagnosed Prevalent Population in Idiopathic Pulmonary Fibrosis (IPF) patients in Japan

6. Treatment

  • 6.1. Treatments with a Peripheral Site of Action
    • 6.1.1. TRP Channels
    • 6.1.2. Purinergic Receptors
    • 6.1.3. Voltage-Gated Sodium Channels
  • 6.2. Treatments with a Central Site of Action
    • 6.2.1. Opiates (Morphine Sulphate/Codeine/Tramadol)
    • 6.2.2. GABA-Related Compounds (Gabapentin, Pregabalin)
    • 6.2.3. N-Methyl-D-Aspartate (NMDA) Receptors
    • 6.2.4. Amitriptyline
    • 6.2.5. Tachykinin Receptor Antagonists
    • 6.2.6. Nicotinic Acetylcholine Receptors
  • 6.3. Management of Chronic Cough

7. United States Guideline on Chronic Refractory Cough

  • 7.1. Treatment of Unexplained Chronic Cough CHEST Guideline and Expert Panel Report

8. Unmet Needs

9. Emerging Drugs

  • 9.1. Key Cross Competition
  • 9.2. Gefapixant: Merck
    • 9.2.1. Product Description
    • 9.2.2. Other Developmental Activities
    • 9.2.3. Clinical Development
    • 9.2.4. Product Profile
  • 9.3. Orvepitant Maleate: Nerre Therapeutics
    • 9.3.1. Product Description
    • 9.3.2. Other Developmental Activities
    • 9.3.3. Clinical Development
    • 9.3.4. Product Profile
  • 9.4. BLU-5937: Bellus Health
    • 9.4.1. Product Description
    • 9.4.2. Other Developmental Activities
    • 9.4.3. Clinical Development
    • 9.4.4. Product Profile
  • 9.5. Bradanicline: Attenua
    • 9.5.1. Product Description
    • 9.5.2. Other Developmental Activities
    • 9.5.3. Clinical Development
    • 9.5.4. Product Profile
  • 9.6. RVT-1601: Respivant Sciences
    • 9.6.1. Product Description
    • 9.6.2. Other Developmental Activities
    • 9.6.3. Clinical Development
    • 9.6.4. Product Profile
  • 9.7. S-600918: Shionogi
    • 9.7.1. Product Description
    • 9.7.2. Clinical Development

10. Chronic Refractory Cough: 7 Major Market Analysis

  • 10.1. Key Findings
  • 10.2. Market Size of Chronic Refractory Cough in the 7MM

11. The United States Market Outlook

  • 11.1. United States Market Size
    • 11.1.1. Total Market size of Chronic Refractory Cough
    • 11.1.2. Market Size by Therapies

12. EU-5 Countries: Market Outlook

  • 12.1. Germany
    • 12.1.1. Total Market size of Chronic Refractory Cough in Germany
    • 12.1.2. Market Size by Therapies
  • 12.2. France
    • 12.2.1. Total Market Size of Chronic Refractory Cough
    • 12.2.2. Market Size by Therapies
  • 12.3. Italy
    • 12.3.1. Total Market Size of Chronic Refractory Cough
    • 12.3.2. Market Size by Therapies
  • 12.4. Spain
    • 12.4.1. Total Market Size of Chronic Refractory Cough
    • 12.4.2. Market Size by Therapies
  • 12.5. United Kingdom
    • 12.5.1. Total Market Size of Chronic Refractory Cough
    • 12.5.2. Market Size by Therapies
  • 12.6. Japan: Market Outlook
    • 12.6.1. Japan Market Size
      • 12.6.1.1. Total Market Size of Chronic Refractory Cough
      • 12.6.1.2. Market Size by Therapies

13. Market Drivers

14. Market Barriers

15. Appendix

  • 15.1. Report Methodology

16. DelveInsight Capabilities

17. Disclaimer

18. About DelveInsight

Back to Top